Principal Investigator - Lisa M. Guay-Woodford, MD
Dr. Lisa M. Guay-Woodford is the Hudson Professor of Pediatrics at Children's National, a pediatric nephrologist, and an internationally-recognized investigator whose research focuses on identifying clinical and genetic factors involved in the pathogenesis of inherited renal disorders, most notably autosomal recessive polycystic kidney disease (ARPKD). Her research program has been funded by the NIH, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and the Polycystic Kidney Disease Foundation. In 2009, Dr. Guay-Woodford was awarded the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease, given by the PKD Foundation and the International Society of Nephrology.
In addition to her clinical and investigative work, Dr. Guay-Woodford is a leader in promoting clinical and translational science. In 2005, she established the UAB Hepato-Renal Fibrocystic Disease Research and Translational Core Center, funded by a NIDDK P30 award. She served as Center Director from 2005 to 2012. Since moving to Children's National in 2012, she has continued to serve as Center co-Director. In 2008, Dr. Guay-Woodford was the founding Director of the UAB Center for Clinical and Translational Science, funded by the NIH CTSA program. Currently, she is the Director of the Children's National Center for Translational Science, as well as Director of the Clinical and Translational Science Institute at Children’s National (CTSI-CN), which is also funded by the NIH CTSA program.
Co-Principal Investigator - Robert H. Miller, PhD
Dr. Robert H. Miller is the Senior Associate Dean for Research in the School of Medicine and Health Sciences at the George Washington University. His research focuses on understanding the cellular and molecular basis of glial cell development in the vertebrate CNS and neural responses to injury and disease. Dr. Miller has focused much of his work on the generation of oligodendrocytes, the myelinating cells of the CNS, and understanding the pathology of demyelinating diseases such as multiple sclerosis. His laboratory has been continually funded for 30 years and he has served on multiple review panels and is currently a member of the scientific advisory board for the Shriners Hospitals, The National Multiple Sclerosis Society, Target ALS and the New York and Maryland Stem Cell programs.
In addition to his discovery research, Dr. Miller is committed to the development of new therapeutic approaches to treat neural disorders. He holds a number of patents and is a founder member of the Myelin Repair Foundation whose goal is to accelerate the discovery and delivery of new treatments for Multiple Sclerosis. He has collaborated closely with a number of biotech companies to help bring new treatments for myelin disorders to the clinic.